Supportive Care

Adolescents and young adults (AYAs) with cancer often wait too long to discuss their end-of-life preferences, or they do not discuss those preferences at all and pass away in a manner that is against their wishes.
Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD)
This section provides a quick update of symptomatic conditions in oncology and their management.
Delaying medication processing is common, especially when it comes to oral cancer therapies. Oncologists at 3 oncology clinics looked at such barriers and the potential impact on patient outcomes.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
Patients receiving allogeneic hematopoietic stem-cell transplant (HSCT) have high rates of vancomycin-resistant enterococci (VRE) upon admission for transplantation.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emerging problem with newer oral anticancer drugs.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading.
Although patient self-reporting of symptoms has been shown to improve longitudinal tracking of symptoms and increase patient engagement in their care, these assessment tools are often underutilized in clinical care.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emergent problem with newer oral anticancer drugs.
Page 1 of 20
Results 1 - 10 of 198